SAN DIEGO, Sept. 11, 2018 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced Richard Vogel, Ph.D., DABNM, FASNM, director of Strategic Initiatives at NuVasive Clinical ServicesTM (NCS), will co-chair, moderate and lecture at the American Society of Neurophysiological Monitoring (ASNM) 2018 Fall Symposium held September 15-16, 2018, in Nashville, Tennessee. ASNM is the largest professional society in the world dedicated to the advancement of intraoperative neurophysiological monitoring (IONM).
Dr. Vogel is a board-certified oversight neurophysiologist and is one of the leading experts in the field of neurophysiology. He is currently the President-Elect of the ASNM, and as the co-chair and moderator of this year's Fall Symposium, will lecture on the major trends in IONM literature and discuss how strong communication and teamwork in the operating room (OR) can optimize patient care.
NCS is the nation's leading provider of IONM services to surgeons and healthcare facilities, and a gold-level sponsor at the ASNM 2018 Fall Symposium. NCS is comprised of approximately 550 highly-trained neurologists and neurophysiologists who have exclusive access to proprietary IONM technology to provide real-time updates on a patient's nervous system during surgery to help maintain patient safety and promote better clinical decision making.
"I am extremely proud to take on this ASNM leadership position as President-Elect to help further shape the IONM profession," said Dr. Vogel. "The more opportunities we have for education and training, to cultivate research and broadly communicate the clinical benefits of IONM, the better insights we can offer in the OR to increase safety and improve outcomes; both of which lead to higher-quality patient care."
Dr. Vogel earned Ph.D.'s in both neuroscience and psychology from Indiana University, and completed a post-doctoral fellowship in neurophysiology at the University of Pennsylvania School of Medicine, as well as an intraoperative clinical neurophysiology fellowship with Surgical Monitoring Associates in Springfield, Pennsylvania. He is the author of multiple IONM peer-reviewed papers and book chapters, and lectures around the world on clinical neurophysiology.
In addition to his leadership role at ASNM and their 2018 Fall Symposium, Dr. Vogel co-founded the new Section on IONM within the North American Spine Society (NASS). He will co-chair the IONM Section's first symposium at this year's NASS Annual Meeting held September 26-29, 2018 in Los Angeles, California.
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
SOURCE NuVasive, Inc.